<DOC>
	<DOCNO>NCT01041833</DOCNO>
	<brief_summary>BACKGROUND Platinum-based chemotherapy ( CT ) standard treatment advance non-small-cell lung cancer ( NSCLC ) . Unfortunately , survival response rate ( RR ) CT poor . There great interest new treatment strategy . One new strategy include use retinoids atRA . The synergistic effect cytotoxic agent retinoids demonstrate lung cancer . At INCan , work group carry phase II study trial include 107 patient advanced NSCLC . They randomize receive atRA ( 20-mg/m2 ) placebo combine 80 mg/m2 cisplatin 175 mg/m2 paclitaxel . The result show significant increase RR atRA group , reach 55.8 % ( 95 % CI ; 46.6-64.9 % ) compare 25.4 % ( 95 % CI , 21.3-29.5 % ; p = 0.001 ) patient receive placebo . Median Progression-free survival ( PFS ) atRA group 8.9 month , placebo , PFS 6.0 month ( p = 0.008 ) . There significant difference grade 3-4 side effect group , except hypertriglycemia , present great frequency atRA group ( p = 0.05 ) . Immunohistochemical stain determine RAR B2 expression 6 60 tumor sample analyze ; however , sample express RAR B2 adjacent normal tissue . HYPOTHESIS Patients NSCLC receive scheme combine first-line CT plus 45 mg/m2 atRA great PFS RR CT acceptable toxicological profile . OBJECTIVES 1 . Obtain great RR CT PFS patient advance NSCLC receive cisplatin- paclitaxel-based CT combine 45-mg/m2 daily dose atRA acceptable toxicological profile . 2 . Evaluate benefit RAR beta RAR alfa expression response biomarker . METHODS Three hundred thirty patient advance NSCLC include receive Paclitaxel 175 mg/m2 Cisplatin 80 mg/m2 ( PC ) every 21 day 6 cycle . Patients randomize receive ATRA 45 mg2/day placebo 1 week treatment complete six cycle . Imaging study perform prior two cycle CT ass response . RAR beta RAR alfa expression analyze immunohistochemistry lung tumoral tissue adjacent lung tissue .</brief_summary>
	<brief_title>Effect All-trans Retinoic Acid With Chemotherapy Based Paclitaxel Cisplatin As First-line Treatment Patients With Advanced Non-small Cell Lung Cancer Expression RAR-alfa RAR-beta Response Biomarker</brief_title>
	<detailed_description>BACKGROUND Platinum-based chemotherapy ( CT ) standard treatment advance non-small-cell lung cancer ( NSCLC ) . Unfortunately , survival response rate ( RR ) CT poor . There great interest new treatment strategy . One new strategy include use retinoids atRA . The synergistic effect cytotoxic agent retinoids demonstrate lung cancer . At INCan , work group carry phase II study trial include 107 patient advanced NSCLC . They randomize receive atRA ( 20-mg/m2 ) placebo combine 80 mg/m2 cisplatin 175 mg/m2 paclitaxel . The result show significant increase RR atRA group , reach 55.8 % ( 95 % CI ; 46.6-64.9 % ) compare 25.4 % ( 95 % CI , 21.3-29.5 % ; p = 0.001 ) patient receive placebo . Median Progression-free survival ( PFS ) atRA group 8.9 month , placebo , PFS 6.0 month ( p = 0.008 ) . There significant difference grade 3-4 side effect group , except hypertriglycemia , present great frequency atRA group ( p = 0.05 ) . Immunohistochemical stain determine RAR beta 2 expression 6 60 tumor sample analyze ; however , sample express RAR beta 2 adjacent normal tissue . HYPOTHESIS Patients NSCLC receive scheme combine first-line CT plus 45 mg/m2 atRA great PFS RR CT acceptable toxicological profile . OBJECTIVES 1 . Obtain great RR CT PFS patient advance NSCLC receive cisplatin- paclitaxel-based CT combine 45-mg/m2 daily dose atRA acceptable toxicological profile . 2 . Evaluate benefit RAR beta RAR alfa expression response biomarker . METHODS Three hundred thirty patient advance NSCLC include receive Paclitaxel 175 mg/m2 Cisplatin 80 mg/m2 ( PC ) every 21 day 6 cycle . Patients randomize receive ATRA 45 mg2/day placebo 1 week treatment complete six cycle . Imaging study perform prior two cycle CT ass response . RAR beta RAR alfa expression analyze immunohistochemistry lung tumoral tissue adjacent lung tissue . POPULATON AND SAMPLE The institution recruit patient National Institute Cancerology ( INCan ) National Institute Respiratory Diseases ( INER ) accord inclusion exclusion criterion protocol : Inclusion criterion : Patients advance NSCLC ( stage III B IV accord Tumor node metastasis [ TNM ] classification ) receive paclitaxel 175 mg/m2- cisplatin-based palliative therapy every 3 week 4 cycle ; general status Karnofsky score ≥70 % , Eastern Cooperative Oncology Group ( ECOG ) ≤2 , hepatic hematic cytology test within normal range , creatinine purification &gt; 75 ml per min , accept participate study , sign letter inform consent . Exclusion criterion : Patients comorbidity another type cancer refuse enter protocol ; patient require reduction chemotherapy dose due alteration laboratory examination ; patient poor general health state ; absence histological diagnosis , previous treatment chemotherapy . Statistical analysis With purpose description , continuous variable express arithmetic mean , median , Standard deviation ( SDs ) , variable category proportion 95 % confidence interval ( 95 % CIs ) . Inferential comparison conduct mean Student test Mann-Whitney U test accord data distribution ( normal non-normal , respectively ) determine Kolmogorov-Smirnov test , example , comparison age mean group . The X2 test Fisher exact test employ evaluate significance among categorical variable , example , group ( atRA vs. placebo ) ECOG high low 80 , stage IIIB vs. IV , history smoking , RAR expression , response . Statistical significance determine p value ( p &lt; 0.05 ) two-tailed test . PFS GS time determine day initiation chemotherapy date death , respectively , analyze Kaplan-Meier test . Comparisons group perform log-rank test . All variable dichotomize analysis survival curve . Adjustment potential confounders perform mean Cox proportion multivariate regression analysis . The SPSS version 15 ( SPSS , Inc. , Chicago , IL , USA ) software package use data analysis .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<criteria>Patients advance NSCLC ( stage III B IV accord Tumor node metastasis [ TNM ] classification ) receive paclitaxel 175 mg/m2 cisplatinbased palliative therapy every 3 week 4 cycle , General status Karnofsky score ≥70 % , Eastern Cooperative Oncology Group ( ECOG ) ≤ 2 , Hepatic hematic cytology test within normal range , Creatinine purification &gt; 75 ml per min , Those accepted participate study , sign letter inform consent . Patients comorbidity another type cancer refuse enter protocol , Patients require reduction chemotherapy dose due alteration laboratory examination , Patients poor general health state Absence histological diagnosis , Previous treatment chemotherapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>All-trans retinoic acid</keyword>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>retinoic acid receptor beta</keyword>
</DOC>